Cargando…

HAA方案治疗复发难治性急性髓系白血病64例疗效观察

OBJECTIVE: To evaluate the efficacy and safety of the HAA regimen (homoharringtonine,cytarabine and aclarubicin) as salvage chemotherapy in the treatment of refractory/relapsed acute myeloid leukemia (AML). METHODS: We retrospectively analyzed 64 patients with refractory/relapsed AML who received th...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348192/
https://www.ncbi.nlm.nih.gov/pubmed/27014977
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.02.003
_version_ 1783556743821787136
collection PubMed
description OBJECTIVE: To evaluate the efficacy and safety of the HAA regimen (homoharringtonine,cytarabine and aclarubicin) as salvage chemotherapy in the treatment of refractory/relapsed acute myeloid leukemia (AML). METHODS: We retrospectively analyzed 64 patients with refractory/relapsed AML who received the HAA regimen as salvage chemotherapy. The complete remission (CR) rate was analyzed. Kaplan-Meier method was used to estimate overall survival (OS) and relapse free survival (RFS), and the differences were compared by Log-rank test. RESULTS: The overall CR rate was 70.1%, and 67.1% of the patients attained CR after the first induction course. The early death rate was 0. The median follow-up time was 61 (range:6–120) months. The estimated 3-year OS rate was 46.8% and the estimated 3-year RFS rate was 42.8%. The CR rates of patients with favorable/intermediate and unfavorable cytogenetics were 76.4% and 33.3%, respectively. The 3-year OS of favorable/intermediate and unfavorable group were 53.7% and 10.0%, respectively. The median survival time of unfavorable group was only 8 months. The side effects associated with the HAA regimen were tolerable, in which the most common toxicities were myelosuppression and infection. CONCLUSION: HAA regimen is associated with a higher rate of CR and longer-term survival and its toxicity can be tolerated. The regimen is suitable for refractory/relapsed AML patients with favorable or intermediate risk.
format Online
Article
Text
id pubmed-7348192
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73481922020-07-16 HAA方案治疗复发难治性急性髓系白血病64例疗效观察 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To evaluate the efficacy and safety of the HAA regimen (homoharringtonine,cytarabine and aclarubicin) as salvage chemotherapy in the treatment of refractory/relapsed acute myeloid leukemia (AML). METHODS: We retrospectively analyzed 64 patients with refractory/relapsed AML who received the HAA regimen as salvage chemotherapy. The complete remission (CR) rate was analyzed. Kaplan-Meier method was used to estimate overall survival (OS) and relapse free survival (RFS), and the differences were compared by Log-rank test. RESULTS: The overall CR rate was 70.1%, and 67.1% of the patients attained CR after the first induction course. The early death rate was 0. The median follow-up time was 61 (range:6–120) months. The estimated 3-year OS rate was 46.8% and the estimated 3-year RFS rate was 42.8%. The CR rates of patients with favorable/intermediate and unfavorable cytogenetics were 76.4% and 33.3%, respectively. The 3-year OS of favorable/intermediate and unfavorable group were 53.7% and 10.0%, respectively. The median survival time of unfavorable group was only 8 months. The side effects associated with the HAA regimen were tolerable, in which the most common toxicities were myelosuppression and infection. CONCLUSION: HAA regimen is associated with a higher rate of CR and longer-term survival and its toxicity can be tolerated. The regimen is suitable for refractory/relapsed AML patients with favorable or intermediate risk. Editorial office of Chinese Journal of Hematology 2016-02 /pmc/articles/PMC7348192/ /pubmed/27014977 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.02.003 Text en 2016年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
HAA方案治疗复发难治性急性髓系白血病64例疗效观察
title HAA方案治疗复发难治性急性髓系白血病64例疗效观察
title_full HAA方案治疗复发难治性急性髓系白血病64例疗效观察
title_fullStr HAA方案治疗复发难治性急性髓系白血病64例疗效观察
title_full_unstemmed HAA方案治疗复发难治性急性髓系白血病64例疗效观察
title_short HAA方案治疗复发难治性急性髓系白血病64例疗效观察
title_sort haa方案治疗复发难治性急性髓系白血病64例疗效观察
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348192/
https://www.ncbi.nlm.nih.gov/pubmed/27014977
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.02.003
work_keys_str_mv AT haafāngànzhìliáofùfānánzhìxìngjíxìngsuǐxìbáixuèbìng64lìliáoxiàoguānchá
AT haafāngànzhìliáofùfānánzhìxìngjíxìngsuǐxìbáixuèbìng64lìliáoxiàoguānchá
AT haafāngànzhìliáofùfānánzhìxìngjíxìngsuǐxìbáixuèbìng64lìliáoxiàoguānchá
AT haafāngànzhìliáofùfānánzhìxìngjíxìngsuǐxìbáixuèbìng64lìliáoxiàoguānchá
AT haafāngànzhìliáofùfānánzhìxìngjíxìngsuǐxìbáixuèbìng64lìliáoxiàoguānchá
AT haafāngànzhìliáofùfānánzhìxìngjíxìngsuǐxìbáixuèbìng64lìliáoxiàoguānchá
AT haafāngànzhìliáofùfānánzhìxìngjíxìngsuǐxìbáixuèbìng64lìliáoxiàoguānchá
AT haafāngànzhìliáofùfānánzhìxìngjíxìngsuǐxìbáixuèbìng64lìliáoxiàoguānchá
AT haafāngànzhìliáofùfānánzhìxìngjíxìngsuǐxìbáixuèbìng64lìliáoxiàoguānchá
AT haafāngànzhìliáofùfānánzhìxìngjíxìngsuǐxìbáixuèbìng64lìliáoxiàoguānchá